Skip to content
10-Q

Quarterly Report

Five Prime Therapeutics, Inc.

0001564590-20-037792

← back to feed
Filed
Aug 6, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2020 · Jul 31, 2020 36.63M sh
Capex Q2 2020 · Jun 30, 2020 $29K
Capex Q2 2020 · Jun 30, 2019 $1.64M
Operating Cash Flow Q2 2020 · Jun 30, 2020 −$36.07M
Operating Cash Flow Q2 2020 · Jun 30, 2019 −$56.33M
Cash And Equivalents Q2 2020 · Jun 30, 2020 $58.71M
Cash And Equivalents Q2 2020 · Dec 31, 2019 $55.8M
Cash And Equivalents Q2 2020 · Jun 30, 2019 $38.31M
Cash And Equivalents Q2 2020 · Dec 31, 2018 $43.95M
Stockholders Equity Q2 2020 · Jun 30, 2020 $119.94M
Stockholders Equity Q2 2020 · Mar 31, 2020 $134.54M
Stockholders Equity Q2 2020 · Dec 31, 2019 $150.47M
Stockholders Equity Q2 2020 · Jun 30, 2019 $206.61M
Stockholders Equity Q2 2020 · Mar 31, 2019 $234.33M
Stockholders Equity Q2 2020 · Dec 31, 2018 $265.14M
Current Liabilities Q2 2020 · Jun 30, 2020 $20.01M
Current Liabilities Q2 2020 · Dec 31, 2019 $23.02M
Current Assets Q2 2020 · Jun 30, 2020 $134.45M
Current Assets Q2 2020 · Dec 31, 2019 $166.72M
Total Assets Q2 2020 · Jun 30, 2020 $185.35M
Total Assets Q2 2020 · Dec 31, 2019 $224.14M
Sga Expense Q2 2020 · Jun 30, 2020 $8M
Sga Expense Q2 2020 · Jun 30, 2020 $18.49M
Sga Expense Q2 2020 · Jun 30, 2019 $9.66M
Sga Expense Q2 2020 · Jun 30, 2019 $20.17M
Rd Expense Q2 2020 · Jun 30, 2020 $12.57M
Rd Expense Q2 2020 · Jun 30, 2020 $31.13M
Rd Expense Q2 2020 · Jun 30, 2019 $29.43M
Rd Expense Q2 2020 · Jun 30, 2019 $61.18M
Net Income Q2 2020 · Jun 30, 2020 −$16.94M
Net Income Q2 2020 · Jun 30, 2020 −$37.05M
Net Income Q2 2020 · Mar 31, 2020 −$20.12M
Net Income Q2 2020 · Jun 30, 2019 −$34.39M
Net Income Q2 2020 · Jun 30, 2019 −$69.78M
Net Income Q2 2020 · Mar 31, 2019 −$35.39M
Operating Income Q2 2020 · Jun 30, 2020 −$17.14M
Operating Income Q2 2020 · Jun 30, 2020 −$37.78M
Operating Income Q2 2020 · Jun 30, 2019 −$35.75M
Operating Income Q2 2020 · Jun 30, 2019 −$72.67M